← Back to Screener
US Stock Screener
HomeScreensNewsWatchlist
...

Phreesia, Inc. (PHR) 10-Year Financial Performance & Capital Metrics

PHR • • Industrial / General
HealthcareHealthcare ITClinical Software & EHR SystemsElectronic Health Record Systems
AboutPhreesia, Inc. provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. Its Phreesia Platform offers a suite of solutions to manage the patient intake process, as well as an integrated payments solution for processing of patient payments. The company deploys its platform in a range of modalities, such as Phreesia Mobile, a patients' mobile device; Phreesia Dashboard, a web-based dashboard for healthcare services clients; PhreesiaPads, which are self-service intake tablets; and Arrivals Kiosks that are on-site kiosks. Its Phreesia Platform also provides a registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, and cost estimation tools; access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking; and life sciences solution to deliver targeted and clinically relevant marketing content to patients. In addition, the company's Phreesia Platform offers clinical support solution, which collects clinical intake and patient reported outcome (PRO) data for approximately 25 specialties, as well as enables healthcare services clients to communicate with their patients through surveys, announcements, text and email messaging, and health campaigns; and COVID-19 support modules for managing COVID-19 vaccine delivery and identify vaccine-hesitant patients, screening for self-reported COVID-19 risk factors, enabling contactless check-in during in-person visits, and collecting intake information during telehealth visits. It serves patients; single-specialty practices, multi-specialty groups, and health systems; and pharmaceutical, medical device, and biotechnology companies. The company was incorporated in 2005 and is headquartered in Raleigh, North Carolina.Show more
  • Revenue $420M +17.8%
  • EBITDA -$30M +71.5%
  • Net Income -$59M +57.2%
  • EPS (Diluted) -1.02 +59.4%
  • Gross Margin 67.86% +4.1%
  • EBITDA Margin -7.2% +75.8%
  • Operating Margin -13.84% +63.9%
  • Net Margin -13.94% +63.7%
  • ROE -22.67% +55.3%
  • ROIC -23.28% +66.3%
  • Debt/Equity 0.07 +41.1%
  • Interest Coverage -24.75 +66.4%
Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

  • ✓Company is almost debt free
  • ✓Strong 5Y sales CAGR of 27.5%
  • ✓Efficient asset utilization: 1.1x turnover

✗Weaknesses

  • ✗Weak momentum: RS Rating 10 (bottom 10%)
  • ✗Trading more than 30% below 52-week high

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-
5Y27.46%
3Y25.33%
TTM14.33%

Profit (Net Income) CAGR

10Y-
5Y-
3Y-
TTM93.5%

EPS CAGR

10Y-
5Y-
3Y-
TTM84.21%

ROCE

10Y Avg-32.74%
5Y Avg-33.4%
3Y Avg-40.17%
Latest-21.73%

Peer Comparison

Electronic Health Record Systems
Select Columns
Size & Scale
Valuation
Per Share
Growth
Profitability
Quality & Returns
Safety & Leverage
TTM Growth
Famous Investor Metrics
Dividends
Latest Quarter
Momentum & Returns
Total Return (DRIP)
Technical
Volume & Trading
Shares & Dilution
Sector-Specific
NameMarket CapCurrent PriceP/E RatioRevenue Growth 1YNet MarginROEFCF YieldDebt/Equity
OMCLOmnicell, Inc.2.28B50.72187.85-3.04%1.69%1.63%6.65%0.31
NUTXNutex Health, Inc.1.17B165.9017.0993.8%11.63%26.04%1.78%1.69
SYSo-Young International Inc.226.9M2.70-0.62-2.09%-51.75%-41.37%0.12
CCLDCareCloud, Inc.121.68M2.87-10.25-5.32%9.8%19.39%15.57%0.07
PHRPhreesia, Inc.971.22M16.11-15.7917.83%-1.16%-1.68%0.85%0.07

Profit & Loss

Jan 2018Jan 2019Jan 2020Jan 2021Jan 2022Jan 2023Jan 2024Jan 2025
Sales/Revenue+79.83M99.89M124.78M148.68M213.23M280.91M356.3M419.81M
Revenue Growth %-0.25%0.25%0.19%0.43%0.32%0.27%0.18%
Cost of Goods Sold+29.77M37M44.72M52.39M81.39M109.27M124.01M134.93M
COGS % of Revenue0.37%0.37%0.36%0.35%0.38%0.39%0.35%0.32%
Gross Profit+50.06M62.89M80.06M96.29M131.84M171.64M232.29M284.88M
Gross Margin %0.63%0.63%0.64%0.65%0.62%0.61%0.65%0.68%
Gross Profit Growth %-0.26%0.27%0.2%0.37%0.3%0.35%0.23%
Operating Expenses+64.62M72.39M95.36M121.96M248.66M348.19M368.77M342.98M
OpEx % of Revenue0.81%0.72%0.76%0.82%1.17%1.24%1.03%0.82%
Selling, General & Admin43.6M46.44M62.81M83.43M175.09M231.65M226.93M197.73M
SG&A % of Revenue0.55%0.46%0.5%0.56%0.82%0.82%0.64%0.47%
Research & Development11.38M14.35M18.62M22.62M52.27M91.24M112.35M117.36M
R&D % of Revenue0.14%0.14%0.15%0.15%0.25%0.32%0.32%0.28%
Other Operating Expenses9.64M11.59M13.92M15.91M21.3M25.3M29.49M27.89M
Operating Income+-14.55M-9.49M-15.3M-25.67M-116.82M-176.55M-136.48M-58.1M
Operating Margin %-0.18%-0.1%-0.12%-0.17%-0.55%-0.63%-0.38%-0.14%
Operating Income Growth %-0.35%-0.61%-0.68%-3.55%-0.51%0.23%0.57%
EBITDA+-3.52M2.1M-1.37M-7.74M-92.3M-147.78M-105.94M-30.21M
EBITDA Margin %-0.04%0.02%-0.01%-0.05%-0.43%-0.53%-0.3%-0.07%
EBITDA Growth %-1.6%-1.65%-4.63%-10.93%-0.6%0.28%0.71%
D&A (Non-Cash Add-back)11.03M11.59M13.92M17.93M24.52M28.77M30.54M27.89M
EBIT-14.55M-9.49M-19.03M-25.55M-116.82M-174.25M-133.49M-53.46M
Net Interest Income+-3.64M-3.5M-2.44M-1.57M-1.08M1.06M2.21M330K
Interest Income401185598K122K79K2.48M4.07M2.68M
Interest Expense3.64M3.5M3.04M1.7M1.16M1.41M1.85M2.35M
Other Income/Expense-3.64M-5.57M-6.78M-1.57M-1.16M889K1.14M2.29M
Pretax Income+-18.19M-15.06M-22.07M-27.24M-117.98M-175.66M-135.34M-55.81M
Pretax Margin %-0.23%-0.15%-0.18%-0.18%-0.55%-0.63%-0.38%-0.13%
Income Tax+0-2.06M-1.78M49K182K483K1.54M2.72M
Effective Tax Rate %1%1%0.92%1%1%1%1.01%1.05%
Net Income+-18.19M-15.06M-20.29M-27.29M-118.16M-176.15M-136.88M-58.53M
Net Margin %-0.23%-0.15%-0.16%-0.18%-0.55%-0.63%-0.38%-0.14%
Net Income Growth %-0.17%-0.35%-0.34%-3.33%-0.49%0.22%0.57%
Net Income (Continuing)-18.19M-15.06M-20.29M-27.29M-118.16M-176.15M-136.88M-58.53M
Discontinued Operations00000000
Minority Interest00000000
EPS (Diluted)+-11.82-8.16-1.00-0.69-2.37-3.36-2.51-1.02
EPS Growth %-0.31%0.88%0.31%-2.43%-0.42%0.25%0.59%
EPS (Basic)-11.82-8.16-1.00-0.69-2.37-3.36-2.51-1.02
Diluted Shares Outstanding1.54M1.84M20.3M39.52M49.89M52.44M54.56M57.59M
Basic Shares Outstanding1.54M1.84M20.3M39.52M49.89M52.44M54.56M57.59M
Dividend Payout Ratio--------

Balance Sheet

Jan 2018Jan 2019Jan 2020Jan 2021Jan 2022Jan 2023Jan 2024Jan 2025
Total Current Assets+35.95M32.88M131.54M272.27M386.35M262.44M195.68M203.28M
Cash & Short-Term Investments10.5M1.54M90.31M218.78M313.81M176.68M87.52M84.22M
Cash Only10.5M1.54M90.31M218.78M313.81M176.68M87.52M84.22M
Short-Term Investments00000000
Accounts Receivable12.31M26.29M21.98M29.05M40.26M51.39M64.86M73.62M
Days Sales Outstanding56.2896.0764.2971.3268.9266.7866.4564.01
Inventory1.64M1.67M6.88M8.95M1.64M1.06M768K0
Days Inventory Outstanding20.116.556.1362.347.363.532.26-
Other Current Assets8.68M1.67M13.26M15.49M21.74M25.94M32.48M34.13M
Total Non-Current Assets+21.18M26.38M27.22M54.4M108.13M107.62M174.64M185.13M
Property, Plant & Equipment13.17M14.21M14.49M29.31M36.98M22.24M17.17M25.13M
Fixed Asset Turnover6.06x7.03x8.61x5.07x5.77x12.63x20.75x16.71x
Goodwill0250.19K250K8.31M33.62M33.74M75.84M75.84M
Intangible Assets6.72M9.25M9.93M13.2M30.41M46.55M77.76M80.91M
Long-Term Investments81.87K01.59M1.25M0000
Other Non-Current Assets1.3M2.67M180K1.67M6.59M5.01M3.87M3.25M
Total Assets+57.14M59.26M158.76M326.67M494.48M370.06M370.33M388.42M
Asset Turnover1.40x1.69x0.79x0.46x0.43x0.76x0.96x1.08x
Asset Growth %-0.04%1.68%1.06%0.51%-0.25%0%0.05%
Total Current Liabilities+24.98M27.93M35.35M54.99M68.43M79.04M110.12M114.02M
Accounts Payable2.2M3.75M6.02M4.39M5.12M10.84M8.48M5.62M
Days Payables Outstanding273749.1130.5822.9636.224.9615.21
Short-Term Debt1.17M97K2.32M4.86M221K246K1.1M1.22M
Deferred Revenue (Current)1000K1000K1000K1000K1000K1000K1000K1000K
Other Current Liabilities8.68M10.22M16.58M24.87M32.45M32.57M53.16M844K
Current Ratio1.44x1.18x3.72x4.95x5.65x3.32x1.78x1.78x
Quick Ratio1.37x1.12x3.53x4.79x5.62x3.31x1.77x1.78x
Cash Conversion Cycle49.3775.5771.31103.0853.3234.1143.75-
Total Non-Current Liabilities+199.84M242.31M21.54M8.37M8.76M3.2M8.76M9.58M
Long-Term Debt19.45M27.92M21.54M6.47M8.7M3.07M2.05M719K
Capital Lease Obligations652.41K2.4M2.1M1.9M8.7M3.07M3.48M8.08M
Deferred Tax Liabilities0002.77M2.71M1.35M270K484K
Other Non-Current Liabilities179.73M211.99M-2.1M0-8.7M-3.07M2.86M185K
Total Liabilities224.82M270.24M56.89M63.36M77.2M82.24M118.88M123.61M
Total Debt+22.93M32.29M23.86M14.32M15.8M9.18M11.98M17.8M
Net Debt12.43M30.74M-66.45M-204.46M-298.01M-167.5M-75.54M-66.42M
Debt / Equity--0.23x0.05x0.04x0.03x0.05x0.07x
Debt / EBITDA-15.37x------
Net Debt / EBITDA-14.64x------
Interest Coverage-4.00x-2.71x-5.03x-15.15x-100.44x-125.13x-73.61x-24.75x
Total Equity+-167.68M-210.97M101.86M263.31M417.28M287.82M251.45M264.81M
Equity Growth %--0.26%1.48%1.58%0.58%-0.31%-0.13%0.05%
Book Value per Share-108.98-114.355.026.668.365.494.614.60
Total Shareholders' Equity-167.68M-210.97M101.86M263.31M417.28M287.82M251.45M264.81M
Common Stock16.38K19.95K366K449K521K542K577K601K
Retained Earnings-167.7M-210.99M-284.49M-311.78M-429.94M-606.08M-742.97M-801.5M
Treasury Stock00-399K-4.96M-13.96M-33.6M-45.52M-45.52M
Accumulated OCI-20.33M-27.86M-158.76M0000-51K
Minority Interest00000000

Cash Flow

Jan 2018Jan 2019Jan 2020Jan 2021Jan 2022Jan 2023Jan 2024Jan 2025
Cash from Operations+-11.14M-2.13M826K2.89M-74.71M-90.12M-32.38M32.38M
Operating CF Margin %-0.14%-0.02%0.01%0.02%-0.35%-0.32%-0.09%0.08%
Operating CF Growth %-0.81%1.39%2.5%-26.85%-0.21%0.64%2%
Net Income-18.19M-15.06M-20.29M-27.29M-118.16M-176.15M-136.88M-58.53M
Depreciation & Amortization9.64M11.59M13.92M15.91M21.3M25.3M29.49M27.89M
Stock-Based Compensation805K1.45M6.18M13.49M36.14M58.77M71.7M66.97M
Deferred Taxes598K2.06M-775K-65K143K434K228K214K
Other Non-Cash Items2.29M1.38M7.54M4.94M4.43M5.37M4.73M2.33M
Working Capital Changes-6.29M-3.55M-5.75M-4.09M-18.57M-3.86M-1.64M-6.49M
Change in Receivables-3.38M-3.8M-5.91M-6.62M-10.22M-11.13M-11.21M-8.81M
Change in Inventory1.65M-2.45M3.37M2.62M0000
Change in Payables-2.06M1.96M-30K-3.82M2.88M4.77M-1.99M-3.23M
Cash from Investing+-11.96M-11.02M-12.32M-25.09M-65.23M-26.2M-39.67M-24.09M
Capital Expenditures-11.96M-9.83M-12.32M-18.57M-30.8M-26.2M-5.81M-8.71M
CapEx % of Revenue0.15%0.1%0.1%0.12%0.14%0.09%0.02%0.02%
Acquisitions--------
Investments--------
Other Investing-5.38M-5.11M-5.3M-7.33M-12.38M-21.47M-19.29M-15.38M
Cash from Financing+31.29M4.19M100.27M150.66M234.97M-20.41M-17.11M-11.49M
Debt Issued (Net)--------
Equity Issued (Net)--------
Dividends Paid00-14.96M00000
Share Repurchases--------
Other Financing-77K165.63K-4.41M6.04M2.42M-20M1.84M-7.61M
Net Change in Cash--------
Free Cash Flow+-23.11M-11.96M-11.49M-15.69M-105.52M-116.33M-57.48M8.29M
FCF Margin %-0.29%-0.12%-0.09%-0.11%-0.49%-0.41%-0.16%0.02%
FCF Growth %-0.48%0.04%-0.36%-5.73%-0.1%0.51%1.14%
FCF per Share-15.02-6.48-0.57-0.40-2.12-2.22-1.050.14
FCF Conversion (FCF/Net Income)0.61x0.14x-0.04x-0.11x0.63x0.51x0.24x-0.55x
Interest Paid0001.47M802K763K1.31M2.19M
Taxes Paid00064K49K39K37K3.07M

Key Ratios

Metric20182019202020212022202320242025
Return on Equity (ROE)---19.92%-14.95%-34.72%-49.96%-50.77%-22.67%
Return on Invested Capital (ROIC)---32.4%-40.85%-98.38%-110.54%-69.11%-23.28%
Gross Margin62.71%62.96%64.16%64.77%61.83%61.1%65.19%67.86%
Net Margin-22.79%-15.08%-16.26%-18.36%-55.41%-62.71%-38.42%-13.94%
Debt / Equity--0.23x0.05x0.04x0.03x0.05x0.07x
Interest Coverage-4.00x-2.71x-5.03x-15.15x-100.44x-125.13x-73.61x-24.75x
FCF Conversion0.61x0.14x-0.04x-0.11x0.63x0.51x0.24x-0.55x
Revenue Growth-25.12%24.92%19.15%43.42%31.74%26.84%17.83%

Revenue by Segment

202020212022202320242025
Subscription And Services56.36M69.04M95.51M128.97M165.44M196.51M
Subscription And Services Growth-22.51%38.34%35.03%28.27%18.78%
Network Solutions---73.57M96.25M121.56M
Network Solutions Growth----30.84%26.30%
Payment Processing Fees46.5M49.9M65.2M78.37M94.61M101.74M
Payment Processing Fees Growth-7.31%30.66%20.19%20.73%7.54%
Life Sciences21.93M29.73M52.52M---
Life Sciences Growth-35.61%76.62%---

Frequently Asked Questions

Growth & Financials

Phreesia, Inc. (PHR) reported $463.2M in revenue for fiscal year 2025. This represents a 480% increase from $79.8M in 2018.

Phreesia, Inc. (PHR) grew revenue by 17.8% over the past year. This is strong growth.

Phreesia, Inc. (PHR) reported a net loss of $5.4M for fiscal year 2025.

Dividend & Returns

Phreesia, Inc. (PHR) has a return on equity (ROE) of -22.7%. Negative ROE indicates the company is unprofitable.

Phreesia, Inc. (PHR) generated $41.9M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

VCP Scanner

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screens
  • Valuation
  • Compare
  • Total Return
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Twitter
  • Get Early Access
© 2026 VCP Scanner. All rights reserved.
Made with ❤️ for investors
Not financial advice. Do your own research.